lenalidomide has been researched along with Diathesis in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bahlis, NJ; Duggan, P; Jimenez-Zepeda, VH; Lee, H; McCulloch, S; Neri, P; Tay, J | 1 |
| Derkach, A; Hassoun, H; Hultcrantz, M; Korde, N; Lesokhin, A; Lu, S; Mailankody, S; Orozco, J; Patel, D; Peterson, T; Piedra, K; Shah, U; Tan, C; Wilkins, CR | 1 |
| Dote, S; Hira, D; Itakura, S; Ito, K; Kobayashi, Y; Noda, S; Terada, T; Yamada, S; Yasu, T | 1 |
| Al Ali, NH; Bart-Smith, E; Craig, BM; Epling-Burnette, PK; Komrokji, RS; Kordasti, S; Kulasekararaj, A; Lancet, JE; List, AF; Mufti, GJ; Padron, E; Pinilla-Ibarz, J; Zhang, L | 1 |
4 other study(ies) available for lenalidomide and Diathesis
| Article | Year |
|---|---|
The impact of COVID-19 in the management of AL amyloidosis and Immunoglobulin Deposition Disease: A single-center experience.
Topics: Aged; Alberta; Antibodies, Monoclonal; Basement Membrane; Bortezomib; COVID-19; COVID-19 Testing; Cyclophosphamide; Dexamethasone; Disease Management; Disease Susceptibility; Drug Therapy, Combination; Female; Humans; Immunoglobulin Light Chains; Immunoglobulin Light-chain Amyloidosis; Kaplan-Meier Estimate; Lenalidomide; Male; Methylprednisolone; Middle Aged; Neoplasm, Residual; Pandemics; Paraproteinemias; Precision Medicine; Retrospective Studies; SARS-CoV-2; Telemedicine | 2021 |
Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide, dexamethasone (KRD) with aspirin or rivaroxaban thromboprophylaxis.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Bortezomib; Dexamethasone; Disease Management; Disease Susceptibility; Female; Humans; Incidence; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Grading; Neoplasm Staging; Oligopeptides; Retrospective Studies; Venous Thromboembolism | 2022 |
Impact of prior bortezomib therapy on the incidence of lenalidomide-induced skin rash in multiple myeloma: a propensity score-matched multi-institutional cohort study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cohort Studies; Disease Susceptibility; Eosinophilia; Exanthema; Female; Humans; Incidence; Lenalidomide; Male; Multiple Myeloma; Propensity Score | 2019 |
Autoimmune diseases and myelodysplastic syndromes.
Topics: Adult; Aged; Aged, 80 and over; Autoimmune Diseases; Azacitidine; Comorbidity; Disease Progression; Disease Susceptibility; Female; Follow-Up Studies; Hashimoto Disease; Humans; Immunocompromised Host; Immunosuppressive Agents; Kaplan-Meier Estimate; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prevalence; Proportional Hazards Models; Retrospective Studies; Thalidomide; Thyroiditis, Autoimmune; Young Adult | 2016 |